Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on July 8, 2005
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyi126
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
35/8/427    most recent
hyi126v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chen, H.-W.
Right arrow Articles by Hwang, J.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, H.-W.
Right arrow Articles by Hwang, J.-J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Foundation for Promotion of Cancer Research
Received February 20, 2005
Accepted May 29, 2005

Original Article

Change of Plasma Transforming Growth Factor-{beta}1 Levels in Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemo-radiotherapy

Hong-Wen Chen 1, Yue-Cune Chang 2, Yuen-Liang Lai 3, Yu-Jen Chen 3, Ming-Jer Huang 4, Yi-Shing Leu 5, Ying-Kai Fu 6, Ling-Wei Wang 7, and Jeng-Jong Hwang 8*

1 Institute of Radiological Sciences, National Yang-Ming University and Mackay Junior College of Nursing, Mackay Memorial Hospital, Tamsui, Taiwan; Department of Radiation Oncology & Hospice Center, Mackay Memorial Hospital, Tamsui, Taiwan
2 Department of Mathematics, Tamkang University, Tamsui, Taiwan
3 Department of Radiation Oncology & Hospice Center, Mackay Memorial Hospital, Tamsui, Taiwan
4 Department of Medical Oncology, Mackay Memorial Hospital, Tamsui, Taiwan
5 Department of Otorhinolaryngology, Mackay Memorial Hospital, Tamsui, Taiwan
6 Institute of Nuclear Energy Research, Taoyuan, Taiwan
7 Department of Radiation Oncology, Taipei Veterans General Hospital, Taipei, Taiwan
8 Institute of Radiological Sciences, National Yang-Ming University and Mackay Junior College of Nursing, Mackay Memorial Hospital, Tamsui, Taiwan

* To whom correspondence should be addressed.
Jeng-Jong Hwang, E-mail: jjhwang{at}ym.edu.tw


  Abstract

Objective: Our aim was to study the correlation between plasma transforming growth factor (TGF)-{beta}1 level and radiation-induced mucositis and dermatitis in nasopharyngeal carcinoma (NPC) patients.

Methods: Blood samples obtained from patients treated with concurrent chemo-radiotherapy (CCRT) were divided into two groups according to the pre-treatment plasma TGF-{beta}1 level (≥7.5 ng/ml as group 1 and <7.5 ng/ml as group 2). Enzyme-linked immunosorbent assay (ELISA) was used for the measurement of the TGF-{beta}1 level. Radiation toxicity was evaluated according to Radiation Treatment Oncology Group criteria. Data were analyzed by the generalized estimation equation method.

Results: TGF-{beta}1 levels of group 1 patients were decreased significantly (P = 0.002) at the end of the treatment. The rate of decrease was 0.12 ng/ml per fraction (P = 0.02). The average TGF-{beta}1 level in patients who suffered acute radiation morbidity (grade ≥2) was significantly higher (P = 0.0057) than that of those who suffered less (grade <2).

Conclusion: A lower pre-treatment plasma TGF-{beta}1 level and the grade of radiation toxicity both appeared to contribute to the elevated plasma TGF-{beta}1 after CCRT.

Keywords: transforming growth factor-{beta}1 (TGF-{beta}1); nasopharyngeal carcinoma; concurrent chemo-radiotherapy.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.